{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:58:53Z","timestamp":1791939533325,"version":"4.3.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"9-10","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:p>Antisense oligonucleotide (ASO)-mediated exon skipping can restore the open reading frame of dystrophin transcripts for Duchenne muscular dystrophy (DMD) patients. This allows production of internally deleted dystrophin proteins as found in the later onset, less severely progressive Becker muscular dystrophy. At present, ASOs that induce exon skipping and dystrophin restoration are approved for the treatment of DMD by the regulatory agencies of the United States and Japan. However, approval was based on restoration of very small amounts of dystrophin and the approved ASOs apply to only a subset of patients. This expert perspective evaluates ways to improve ASO efficiency that are currently in or close to clinical trials, as well as ways to improve applicability of this mutation-specific approach.<\/jats:p>","DOI":"10.1089\/hum.2023.026","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T05:40:57Z","timestamp":1678945257000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":38,"title":["The Future of Exon Skipping for Duchenne Muscular Dystrophy"],"prefix":"10.1177","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1565-654X","authenticated-orcid":false,"given":"Annemieke","family":"Aartsma-Rus","sequence":"first","affiliation":[{"name":"Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90383-2"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805263182104"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2169070"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.1.42"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.15.1547"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/154545704322988030"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0845"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1288"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac641"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2022.08.019"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.120"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.72"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00924-7"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.02.012"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn293"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy377"},{"key":"e_1_3_4_19_2","unstructured":"Sarapta Therapeutics. 2021. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-reports-positive-clinical-results-phase-2 [Last accessed: April 18 2023]."},{"key":"e_1_3_4_20_2","unstructured":"Pepgen. 2022. Available from: https:\/\/investors.pepgen.com\/news-releases\/news-release-details\/pepgen-reports-positive-data-phase-1-trial-pgn-edo51-treatment [Last accessed: April 18 2023]."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00012.2014"},{"key":"e_1_3_4_22_2","unstructured":"Entrada Therapeutics. 2022. Available from: https:\/\/ir.entradatx.com\/news-releases\/news-release-details\/entrada-therapeutics-announces-clinical-hold-ind-application [Last accessed: April 18 2023]."},{"key":"e_1_3_4_23_2","unstructured":"Sarepta Therapeutics. 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04004065?term=vesleteplirsen&draw=2&rank=3 [Last accessed: April 18 2023]."},{"key":"e_1_3_4_24_2","unstructured":"Avidity bioscience. 2023. Available from: https:\/\/ HYPERLINK http:\/\/www.aviditybiosciences.com\/pipeline\/dmd\/ [Last accessed: April 18 2023]."},{"key":"e_1_3_4_25_2","unstructured":"BioMarin. 2021. Available from: https:\/\/www.biomarin.com\/wp-content\/uploads\/2021\/10\/BioMarin-DMD-Clinical-Program-Update-04OCT2021_Archive.pdf [Last accessed: April 18 2023]."},{"key":"e_1_3_4_26_2","unstructured":"Wave Life Sciences. 2019. Available from: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-discontinuation-suvodirsen [Last accessed: April 18 2023]."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac018"},{"key":"e_1_3_4_28_2","unstructured":"Wave Life Sciences. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04906460?term=NCT04906460&draw=2&rank=1 [Last accessed: April 18 2023]."},{"key":"e_1_3_4_29_2","unstructured":"Wave Life Sciences. 2022. Available from: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-provides-positive-update-proof-concept-study [Last accessed: April 18 2023]."},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.1"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104297"},{"key":"e_1_3_4_32_2","unstructured":"Audentes Therapeutics. 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04240314?term=NCT04240314&draw=2&rank=1 [Last accessed: April 18 2023]."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.07.005"},{"key":"e_1_3_4_34_2","unstructured":"Parent project musculara dystrophy. 2022. Available from: https:\/\/www.parentprojectmd.org\/nationwide-childrens-hospital-announces-restoration-of-full-length-dystrophin-using-duplication-2-gene-therapy-approach\/#:\u223c:text=Researchers%20at%20Nationwide%20Children%27s%20Hospital Duchenne%20muscular%20dystrophy%20(DMD). Nationwide Children's Announces Restoration of Full-Length Dystrophin Using Dup 2 Gene Therapy Approach\u2014Parent Project Muscular Dystrophy (parentprojectmd.org) [Last accessed: April 18 2023]."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1580"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.06.012"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.09.016"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20918"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"e_1_3_4_40_2","first-page":"1","article-title":"The dilemma of choice for duchenne patients eligible for exon 51 skipping the European experience","author":"Aartsma-Rus A","year":"2023","unstructured":"Aartsma-Rus A, , De Waele L, , Houwen-Opstal S, et al. The dilemma of choice for duchenne patients eligible for exon 51 skipping the European experience. J Neuromusc Dis, 2023; Preprint:1\u201311.","journal-title":"J Neuromusc Dis"},{"key":"e_1_3_4_41_2","unstructured":"Cure Duchenne. 2022. Available from: https:\/\/cureduchenne.org\/research\/ns-pharma-study-shows-exon-44-skipping-drug-efficacy\/ NS Pharma Study Shows Exon 44 Skipping Drug Efficacy\u2014CureDuchenne [Last accessed: April 18 2023]."},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M709410200"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193289"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244215"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.76"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-9-105"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112546119"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7244"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201626"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180357"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2023.026","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2023.026","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2023.026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:58Z","timestamp":1777449418000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2023.026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":49,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1089\/hum.2023.026"],"URL":"https:\/\/doi.org\/10.1089\/hum.2023.026","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}